Home Healthcare IT Pain Management Market Size, Top Share, Demand | Industry Report, 2034

Pain Management Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Anticonvulsants, Antidepressants, Anti-migraine agents, Non-narcotic analgesics, Opioids), By Route of Administration (Oral, Parenteral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Report Code: SRHI54528DR
Last Updated: Mar, 2026
Pages: 160
Author: Debashree Bora
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Pain Management Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. NSAIDs
        1. By Value
      3. Anticonvulsants
        1. By Value
      4. Antidepressants
        1. By Value
      5. Anti-migraine agents
        1. By Value
      6. Non-narcotic analgesics
        1. By Value
      7. Opioids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. NSAIDs
        1. By Value
      3. Anticonvulsants
        1. By Value
      4. Antidepressants
        1. By Value
      5. Anti-migraine agents
        1. By Value
      6. Non-narcotic analgesics
        1. By Value
      7. Opioids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. NSAIDs
          1. By Value
        3. Anticonvulsants
          1. By Value
        4. Antidepressants
          1. By Value
        5. Anti-migraine agents
          1. By Value
        6. Non-narcotic analgesics
          1. By Value
        7. Opioids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. NSAIDs
        1. By Value
      3. Anticonvulsants
        1. By Value
      4. Antidepressants
        1. By Value
      5. Anti-migraine agents
        1. By Value
      6. Non-narcotic analgesics
        1. By Value
      7. Opioids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. NSAIDs
          1. By Value
        3. Anticonvulsants
          1. By Value
        4. Antidepressants
          1. By Value
        5. Anti-migraine agents
          1. By Value
        6. Non-narcotic analgesics
          1. By Value
        7. Opioids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. NSAIDs
        1. By Value
      3. Anticonvulsants
        1. By Value
      4. Antidepressants
        1. By Value
      5. Anti-migraine agents
        1. By Value
      6. Non-narcotic analgesics
        1. By Value
      7. Opioids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. NSAIDs
          1. By Value
        3. Anticonvulsants
          1. By Value
        4. Antidepressants
          1. By Value
        5. Anti-migraine agents
          1. By Value
        6. Non-narcotic analgesics
          1. By Value
        7. Opioids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. NSAIDs
        1. By Value
      3. Anticonvulsants
        1. By Value
      4. Antidepressants
        1. By Value
      5. Anti-migraine agents
        1. By Value
      6. Non-narcotic analgesics
        1. By Value
      7. Opioids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. NSAIDs
          1. By Value
        3. Anticonvulsants
          1. By Value
        4. Antidepressants
          1. By Value
        5. Anti-migraine agents
          1. By Value
        6. Non-narcotic analgesics
          1. By Value
        7. Opioids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. NSAIDs
        1. By Value
      3. Anticonvulsants
        1. By Value
      4. Antidepressants
        1. By Value
      5. Anti-migraine agents
        1. By Value
      6. Non-narcotic analgesics
        1. By Value
      7. Opioids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. NSAIDs
          1. By Value
        3. Anticonvulsants
          1. By Value
        4. Antidepressants
          1. By Value
        5. Anti-migraine agents
          1. By Value
        6. Non-narcotic analgesics
          1. By Value
        7. Opioids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Pain Management Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Pfizer
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Johnson & Johnson
    3. Eli Lilly and Company
    4. Novartis
    5. GlaxoSmithKline
    6. Sanofi
    7. Bayer
    8. AstraZeneca
    9. Endo International
    10. Mallinckrodt
    11. Boston Scientific Corporation 
    12. Vertex Pharmaceuticals
    13. ElectroCore
    14. Nalu Medical
    15. Neurometrix
    16. BehaVR
    17. Saluda Medical Pty Ltd. 
    18. SPR Therapeutics
    19. Mainstay Medical
    20. SetPoint Medical
    21. EndoStim
    22. Neuros Medical
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Straits Research
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.